Panoskaltsis-Mortari A - Search Results

1

Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.

Fulton LM, Taylor NA, Coghill JM, West ML, Föger N, Bear JE, Baldwin AS, Panoskaltsis-Mortari A, Serody JS. Fulton LM, et al. Eur J Immunol. 2014 Jun;44(6):1662-71. doi: 10.1002/eji.201344155. Eur J Immunol. 2014. PMID: 24752751 Free PMC article.

2

Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.

Buhlmann JE, Gonzalez M, Ginther B, Panoskaltsis-Mortari A, Blazar BR, Greiner DL, Rossini AA, Flavell R, Noelle RJ. Buhlmann JE, et al. J Immunol. 1999 Apr 15;162(8):4373-6. J Immunol. 1999. PMID: 10201970

3

T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.

Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR. Serody JS, et al. Blood. 2000 Nov 1;96(9):2973-80. Blood. 2000. PMID: 11049973 Free article.

4

The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.

Gonzalez M, Quezada SA, Blazar BR, Panoskaltsis-Mortari A, Rudensky AY, Noelle RJ. Gonzalez M, et al. J Immunol. 2002 Nov 15;169(10):5581-9. doi: 10.4049/jimmunol.169.10.5581. J Immunol. 2002. PMID: 12421935

5

Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice.

Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Serody JS, Blazar BR. Panoskaltsis-Mortari A, et al. Blood. 2003 May 1;101(9):3714-21. doi: 10.1182/blood-2002-08-2465. Epub 2003 Jan 2. Blood. 2003. PMID: 12511416 Free article.

6

In vivo imaging of graft-versus-host-disease in mice.

Panoskaltsis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody JS, Blazar BR. Panoskaltsis-Mortari A, et al. Blood. 2004 May 1;103(9):3590-8. doi: 10.1182/blood-2003-08-2827. Epub 2004 Jan 8. Blood. 2004. PMID: 14715632 Free article.

7

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ. Sun K, et al. Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5. doi: 10.1073/pnas.0401563101. Epub 2004 May 17. Proc Natl Acad Sci U S A. 2004. PMID: 15148407 Free PMC article.

8

Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning.

Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL, Luster AD, McKinnon K, Blazar BR, Serody JS. Wysocki CA, et al. J Immunol. 2004 Jul 15;173(2):845-54. doi: 10.4049/jimmunol.173.2.845. J Immunol. 2004. PMID: 15240671

9

L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.

Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, June CH, Serody JS, Blazar BR. Taylor PA, et al. Blood. 2004 Dec 1;104(12):3804-12. doi: 10.1182/blood-2004-05-1850. Epub 2004 Aug 3. Blood. 2004. PMID: 15292057 Free article.

10

CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease.

Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, Roskos M, Serody JS, Yagita H, Podack ER, Taylor PA. Blazar BR, et al. J Immunol. 2004 Sep 1;173(5):2933-41. doi: 10.4049/jimmunol.173.5.2933. J Immunol. 2004. PMID: 15322151

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

267 results

Search Page

Filters